NCT06066710

Propranolol in Primary Progressive Aphasia

Trial of Propranolol in Older Adults with Primary Progressive Aphasia

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University of Missouri-Columbia · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.

Conditions

• Aphasia, Primary Progressive

Interventions

Type	Name	Description
DRUG	Propranolol	Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
DEVICE	Magnetic Resonance Imaging (MRI)	Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.
DRUG	Placebo	Placebo will be given on the same schedule as the propranolol regime.

Timeline

• Start date: 2025-01-13
• Primary completion: 2026-12-01
• Completion: 2027-12-01
• First posted: 2023-10-04
• Last updated: 2025-03-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study